Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial

Vaccine (2022) - Comments
pubmed: 35501178 doi: 10.1016/j.vaccine.2022.04.035 issn: 0264-410x issn: 1873-2518

Taisei Masuda, Kyoko Murakami, Kenkichi Sugiura, Sho Sakui, Ron P Schuring, Mitsuhiro Mori